Multi-Biomarker Pattern for Tumor Identification and Prognosis

被引:25
作者
Rodriguez-Enriquez, Sara [1 ,2 ]
Cecilia Pacheco-Velazquez, Silvia [1 ]
Carlos Gallardo-Perez, Juan [1 ]
Marin-Hernandez, Alvaro [1 ]
Luis Aguilar-Ponce, Jose [2 ]
Ruiz-Garcia, Erika [2 ]
Maria RuizGodoy-Rivera, Luz [2 ,3 ]
Meneses-Garcia, Abelardo [2 ,3 ]
Moreno-Sanchez, Rafael [1 ]
机构
[1] Inst Nacl Cardiol, Dept Biochem, Tlalpan, Mexico
[2] Inst Nacl Cancerol, Lab Translat Med, Tlalpan, Mexico
[3] Inst Nacl Cancerol, Dept Tumor Bank, Tlalpan, Mexico
关键词
METABOLIC BIOMARKERS; BIOMARKER PATTERNS; HIF-1; alpha; GLYCOLYTIC GENES; CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; LYSYL OXIDASE EXPRESSION; METASTATIC BREAST-CANCER; INDUCIBLE FACTOR 1-ALPHA; SURROGATE END-POINTS; COLORECTAL-CANCER; ESTROGEN-RECEPTOR; OVARIAN-CANCER; MICROSATELLITE ALTERATIONS;
D O I
10.1002/jcb.23224
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In last decades, the basic, clinical, and translational research efforts have been directed to the identification of standard biomarkers associated with the degree of malignancy. There is an increasingly public health concern for earlier detection of cancer development at stages in which successful treatments can be achieved. To meet this urgent clinical demand, early stage cancer biomarkers supported by reliable and robust experimental data that can be readily applicable in the clinical practice, are required. In the current standard protocols, when one or two of the canonical proliferating index biomarkers are analyzed, contradictory results are frequently reached leading to incorrect cancer diagnostic and unsuccessful therapies. Therefore, the identification of other cellular characteristics or signatures present in the tumor cells either alone or in combination with the well-established proliferation markers emerge as an alternative strategy in the improvement of cancer diagnosis and treatment. Because it is well known that several pathways and processes are altered in tumor cells, the concept of "single marker" in cancer results incorrect. Therefore, this review aims to analyze and discuss the proposal that the molecular profile of different genes or proteins in different altered tumor pathways must be established to provide a better global clinical pattern for cancer detection and prognosis. J. Cell. Biochem. 112: 2703-2715, 2011. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:2703 / 2715
页数:13
相关论文
共 144 条
[1]   Lysyl oxidase expression and inhibition in uveal melanoma [J].
Abourbih, Daniel A. ;
Di Cesare, Sebastian ;
Orellana, Maria E. ;
Antecka, Emilia ;
Martins, Claudia ;
Petruccelli, Luca A. ;
Burnier, Miguel N., Jr. .
MELANOMA RESEARCH, 2010, 20 (02) :97-106
[2]   Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC) [J].
Albinger-Hegyi, Andrea ;
Stoeckli, Sandro J. ;
Schmid, Stephan ;
Storz, Martina ;
Iotzova, Guergana ;
Probst-Hensch, Nicole M. ;
Rehrauer, Hubert ;
Tinguely, Marianne ;
Moch, Holger ;
Hegyi, Ivan .
INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (11) :2653-2662
[3]   Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer [J].
Allegra, CJ ;
Parr, AL ;
Wold, LE ;
Mahoney, MR ;
Sargent, DJ ;
Johnston, P ;
Klein, P ;
Behan, K ;
O'Connell, MJ ;
Levitt, R ;
Kugler, JW ;
Tirona, MT ;
Goldberg, RM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1735-1743
[4]   The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer [J].
Allred, DC ;
Brown, P ;
Medina, D .
BREAST CANCER RESEARCH, 2004, 6 (06) :240-245
[5]  
Alsheyab F, 2009, AFR J BIOTECHNOL, V8, P5025
[6]   Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes [J].
Altenberg, B ;
Greulich, KO .
GENOMICS, 2004, 84 (06) :1014-1020
[7]  
[Anonymous], 2005, SYSTEMS BIOL DEFINIT
[8]   HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer [J].
Arens, N ;
Bleyl, U ;
Hildenbrand, R .
VIRCHOWS ARCHIV, 2005, 446 (05) :489-496
[9]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[10]  
Atsumi T, 2002, CANCER RES, V62, P5881